MedTrace Logo

Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis

NCT02443103 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-02-13

Study results available
· View outcomes & findings →

Summary

This study will explore the biologic activity of guanabenz in reducing bone turn over in solid tumor patients with bone metastasis. If successful, this repurposing of an already, generic drug could benefit patients faster than manufacturing a novel expensive compound.

Conditions

  • Bone Cancer
  • Metastasis

Interventions

DRUG

Guanabenz acetate

Sponsors & Collaborators

  • Kathy Miller

    lead OTHER

Principal Investigators

  • Kathy Miller, MD · Indiana University (IU) School of Medicine, Department of Medicine; IU Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-07
Primary Completion
2016-06-08
Completion
2016-06-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02443103 on ClinicalTrials.gov